Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR …
Objectives To summarise, by a systematic literature review (SLR), the evidence regarding
pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat …
pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat …
Discovery of BIIB068: a selective, potent, reversible Bruton's tyrosine kinase inhibitor as an orally efficacious agent for autoimmune diseases
B Ma, T Bohnert, KL Otipoby, E Tien… - Journal of Medicinal …, 2020 - ACS Publications
Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic
role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind …
role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind …
Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis
P Chan, J Yu, L Chinn, M Prohn, J Huisman… - Pharmaceutical …, 2020 - Springer
Abstract Purpose Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was
investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis (RA). Our aim was …
investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis (RA). Our aim was …
[PDF][PDF] Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: as stematic literature re ie informing the EULAR …
PM Welsing - core.ac.uk
Objectives To summarise, by a systematic literature review (SLR), the evidence regarding
pharmacological and non-pharmacological therapeutic strategies in difficult-totreat …
pharmacological and non-pharmacological therapeutic strategies in difficult-totreat …